ClinicalTrials.gg
Not yet recruitingNCT07390994PIX-PHENOUpdated Feb 5, 2026

The PICCOLETO IX PHENO Study

An observational study in Coronary Artery Disease, sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
600
Ages
18 Years and older
Sex
All
01

Study summary

To investigate whether pre-procedural OCT-derived de novo coronary lesion phenotype (lipid-rich, fibrotic, calcific; and ACS mechanisms such as plaque rupture/erosion/calcified nodule) is associated with clinical outcomes after DCB angioplasty.

Read the detailed description

PICCOLETO IX PHENO is an investigator-initiated, multicenter, international, ambispective (retrospective and prospective) cohort study enrolling patients who underwent DCB angioplasty for de novo coronary artery disease with preprocedural OCT assessment of the target segment. OCT images (baseline mandatory; post-preparation and post-PCI when available) and angiography will be analyzed by independent core laboratories; clinical events will be adjudicated by an independent committee. The primary endpoint is clinically-driven target lesion revascularization at 12 months; secondary endpoints include device-oriented composite endpoint (cardiac death, TLR, target-vessel MI), target vessel revascularization, MI endpoints, and mortality.

02

Conditions studied

  • Coronary Artery Disease

Keywords

  • Drug-Coated Balloon
  • Optical Coherence Tomography
  • Percutaneous Coronary Intervention
  • Plaque phenotype
03

In context

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

This study's planned enrollment of 600 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Fondazione Ricerca e Innovazione Cardiovascolare ETS is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with chronic coronary syndrome or acute coronary syndrome who underwent drug-coated balloon angioplasty for de novo obstructive coronary artery disease with preprocedural optical coherence tomography assessment of the target segment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic coronary syndrome or acute coronary syndrome diagnosis (per ESC guidelines).
  • De novo obstructive CAD: ≥50% left main stenosis, or any stenosis ≥70%, or FFR \<0.80 in any other major epicardial vessel, or MLA deemed ischemic at intravascular imaging.
  • OCT assessment of the target segment phenotype prior to lesion preparation and DCB angioplasty.
  • Successful DCB angioplasty according to DCB ARC criteria.
  • Patients who underwent DCB-only PCI, or hybrid DCB-DES PCI with at least 20 mm of the target segment treated with DCB.

Exclusion criteria

Exclusion Criteria:

  • Previous revascularization of the target segment with stent.
  • Hybrid DCB-DES PCI with DCB-treated segment \<20 mm and/or lacking complete OCT assessment of the DCB-treated segment and/or bailout stenting.
  • Lack of at least 6 months of clinical follow up.
  • PCI of chronic total occlusion.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
600 participants (estimated)
06

What researchers measure

Primary outcomes

  1. Clinically-driven Target Lesion Revascularization (TLR)

    Any repeat revascularization (percutaneous or surgical) of the target lesion performed for recurrent symptoms or objective evidence of ischemia attributable to the target lesion.

    Time frame: 12 months

Secondary outcomes

  1. Device-Oriented Composite Endpoint (DOCE)

    Composite of cardiac death, target-vessel myocardial infarction, and clinically-driven target lesion revascularization.

    Time frame: 12 months

  2. Target Vessel Revascularization (TVR)

    Any repeat revascularization (percutaneous or surgical) of the target vessel.

    Time frame: 12 months

  3. All-cause Mortality

    Death from any cause during the study follow-up period.

    Time frame: 12 months

  4. Cardiac Death

    Death attributed to cardiovascular causes, including death from unknown cause.

    Time frame: 12 months

  5. Target-Vessel Myocardial Infarction (TV-MI)

    Myocardial infarction attributable to the target vessel based on clinical, electrocardiographic, and biomarker criteria according to the Fourth Universal Definition of Myocardial Infarction.

    Time frame: 12 months

  6. Any Myocardial Infarction

    Any myocardial infarction (target-vessel or non-target-vessel) according to the Fourth Universal Definition of Myocardial Infarction.

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data may be made available to qualified researchers upon reasonable request after study completion and primary publication, subject to appropriate data use agreements and ethics committee approval.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Mar 2027, 14 months later.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 14 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 5, 2026
StartEst.
Jan 9, 2026
Primary completionEst.
Mar 10, 2027
CompletionEst.
Apr 20, 2027
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07390994
Lead sponsor
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Jan 9, 2026 (estimated)
Primary completion
Mar 10, 2027 (estimated)
Completion
Apr 20, 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Filippo Gurguglione
Contact
mailto:filippolucagurgoglione@gmail.com
+393312048150
Beatrice Barbano
Contact
Filippo Luca Gurgoglione
principal investigator · A.O.U. di Parma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion